EFFECTIVENESS AND SAFETY OF CONCOMITANT USE OF PEPTIDE COMPLEX AND DIACEREIN IN OSTEOARTHRITIS OF KNEE JOINT

Эффективность и безопасность совместного применения пептидного комплекса и диацереина при остеоартрите коленного сустава
V.E. Goncharova, Зонова Елена Владимировна
2022-01-01

SYSADOAWOMAC indexdiacereinglycosaminoglycan peptide complexknee osteoarthritis
As part of a prospective study, it was evaluated the efficacy and safety of the combined use of drugs from the group of symptomatic slow acting agents (SYSADOA): Diacerein and glycosaminoglycan peptide complex (GPC) in patients with knee osteoarthritis. The dynamics of pain according to Visual Analoguе Scale (VAS), need for non-steroidal anti-inflammatory drugs, the WOMAC index, EQ-5D score, and OMERACT-OARSI criterion, the presence of adverse events were analyzed, and the effect of Diacerein on the components of the metabolic syndrome was assessed. It was shown that the concomitant use of GPC and Diacerein demonstrated high efficiency and equivalent safety in comparison with the isolated use of GPC: a decrease in the pain intensity in the early stages of therapy, a decrease in the need for NSAIDs, a tendency to improve lipid and purine metabolism.
1
A prospective study evaluated concomitant glycosaminoglycan peptide complex and diacerein for knee osteoarthritis, assessing efficacy, safety, symptoms, quality of life, and metabolic effects.
2
Combination treatment decreased patients’ need for nonsteroidal anti-inflammatory drugs compared with baseline.
3
Combined glycosaminoglycan peptide complex and diacerein reduced pain intensity during the early stages of therapy.
4
Concomitant therapy demonstrated high efficacy and safety equivalent to glycosaminoglycan peptide complex used alone.
5
Diacerein showed a tendency to improve lipid and purine metabolism components associated with metabolic syndrome.

Patients with knee osteoarthritis receiving concomitant glycosaminoglycan peptide complex and diacerein therapy

The efficacy and safety of concomitant therapy, including effects on pain, NSAID use, functional and quality-of-life measures, adverse events, and metabolic-syndrome components

Publication Details
Publication Date
2022-01-01
Journal
Publisher
ISSN
Cited by
0
Access Type
Author Information
Authors
V.E. Goncharova
Зонова Елена Владимировна
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%